Market Currents
Merck (MRK) +3% AH after reporting favorable Phase III trial results for its odnacatib...
-
Wednesday, July 11, 2012, 6:19 PM ETMerck (MRK) +3% AH after reporting favorable Phase III trial results for its odnacatib osteoporosis drug. The company says it will "begin taking steps to close the trial," and plans to submit the drug for approval by U.S., E.U., and Japanese regulators in 1H 2013. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
